Disorder Related to Renal Transplantation
Conditions
Keywords
Kidney transplantation, Immunosuppressive treatment
Brief summary
The aim of the study is to investigate the impact of Anti-Thymocyte Globulin (ATG) on immune senescence. Markers of immune senescence expression is assessed in a prospective cohort of renal transplant recipients the day of transplantation and one year after renal transplantation.
Detailed description
The anti-thymocyte globulin (ATG) are used in the prevention and treatment of acute rejection in organ transplantation. They are at the origin of a brutal CD4 lymphocyte depletion followed by a gradual recovery of the lymphocyte pool. Nevertheless, CD4 lymphopenia can persist in some patients. SIGAL study aims to characterize the immune responses of lymphopenic patients (after administration of ATG) in order to identify possible similarities with immunosenescence.The immunosenescence is a complex and profound remodeling of the immune system during life. It is mainly due to thymic involution and repeated antigenic stimulation.
Interventions
OTHERBlood sample
A blood sample is performed one year after kidney transplantation.
Sponsors
Centre Hospitalier Universitaire de Besancon
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Patient able to understand the reason of the study * Signature of informed consent * Patient who are waiting renal transplant
Exclusion criteria
* Inability to understand the reasons for the study; psychiatric disorders * Any history in the last 2 years of immunosuppressive therapy (except steroids) * History of cancer (except skin cancer) or treated hematological malignancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of senescent lymphocytes | One year after kidney transplantation | Flow cytometry analysis (7 colors) of lymphocytes |
Countries
France
Outcome results
None listed